Blood disease
Conditions
Interventions
Case series:CART cell infusion
Sponsors
Beijing Boren Hospital
Eligibility
Sex/Gender
All
Age
1 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1. With pathological diagnosis of B-cell tumor with positive target markers, primary drug resistance, tumor progression, recurrence during chemotherapy or tumor recurrence after discontinuation, no response for 1 course of chemotherapy, and partial remission cannot be obtained (standard reference NCCN guidelins, version 4, 2014) or chemotherapy 2 course can not achieve complete remission; 2. Aged 1-18 years (including 18 years); 3. A self-knowledgeable 18-year-old patient voluntarily signs the informed consent form, and the legal representative (guardian) of a child patient under 18 years old voluntarily signs the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Combining one or more of the following complications, the patient's condition is in a serious state: (1) High tumor burden, extensive affected areas, corresponding complications, and affecting normal organ function, such as: hyperleukemia, moderate-large amount of serous fluid, severe hypoproteinemia, severe electrolyte disturbance, acid-base balance Disorders, coagulopathy, etc .; (2) Huge tumors compress the surrounding tissues and organs, causing obvious complications, such as airway compression or obstruction, superior vena cava obstruction syndrome, intussusception, incomplete intestinal obstruction, urinary retention, etc .; (3) Central nervous system invasion with or without increased intracranial pressure, such as headache, vomiting, lethargy, irritability, etc.; (4) Combined with hemophagocytic syndrome; (5) Tumor lysis syndrome with varying degrees of electrolyte disturbance, hyperuricemia (blood uric acid> 500umol / L), hyperlactate dehydrogenase (LDH> 500U/L), etc.; (6) Those who have increased breathing, wheezing, or difficulty breathing due to various reasons; (7) Arrhythmias caused by various reasons without severe hemodynamic changes; (8) Patients with myelosuppression caused by bone marrow suppression after chemotherapy with fever, severe reduction of platelets 5.5mmol/L), hyperphosphatemia (blood phosphorus> 1.61 mmol/L), hypocalcemia (serum calcium <2mmol/L or free <1mmol/L), hyperuricemia, impaired renal function, hypertension, oliguria and even anuria; (4) Tumor lysis syndrome secondary to recurrent leukoencephalopathy in the back of the brain; (5) Granulocyte deficiency caused by severe bone marrow suppression after chemotherapy with infection, sepsis, shock, electrolyte disturbances, acid-base balance disorders, severe lung infections, gastrointestinal mucositis, skin and soft tissue infections, etc .; platelet extremely reduced <10,000 mm3 patients with different degrees of bleeding; (6) bleeding of vital organs and life-threatening people, such as pulmonary hemorrhage and cerebral hemorrhage; (7) People with various arrhythmias and hemodynamic changes; (8) Shock, DIC, acute heart, liver, kidney failure and respiratory failure caused by various causes.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety index; | — |
Countries
China
Contacts
Public ContactYonghong Zhang
Beijing Boren Hospital
Outcome results
None listed